Apellis Reports Positive Results from Phase 3 Study Comparing Pegcetacoplan (APL-2) to Eculizumab in PNH Patients

January 16, 2020

Apellis Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through the inhibition of the complement system, announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with PNH.

Top-line data show that pegcetacoplan met the study’s primary efficacy endpoint, demonstrating superiority to eculizumab with a significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16. The safety profile of pegcetacoplan was comparable with eculizumab in this study.

Click here to read the company’s full press release.